Promises of apoptosis-inducing peptides in cancer therapeutics.

Details

Ressource 1Download: 5_21470140_Postprint.pdf (256.57 [Ko])
State: Public
Version: Final published version
Secondary document(s)
Download: 5_21470140_Postprint.pdf (590.48 [Ko])
State: Public
Version: Author's accepted manuscript
Serval ID
serval:BIB_6603E02C972C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Promises of apoptosis-inducing peptides in cancer therapeutics.
Journal
Current Pharmaceutical Biotechnology
Author(s)
Barras D., Widmann C.
ISSN
1873-4316 (Electronic)
ISSN-L
1389-2010
Publication state
Published
Issued date
2011
Volume
12
Number
8
Pages
1153-65
Language
english
Abstract
Until recently, most research efforts aimed at developing anti-cancer tools were focusing on small molecules. Alternative compounds are now being increasingly assessed for their potential anti-cancer properties, including peptides and their derivatives. One earlier limitation to the use of peptides was their limited capacity to cross membranes but this limitation was alleviated with the characterization of cell-permeable sequences. Additionally, means are designed to target peptides to their malignant targets. Most anti-cancer peptidic compounds induce apoptosis of tumor cells by modulating the activity of Bcl-2 family members that control the release of death factors from the mitochondria or by inhibiting negative regulators of caspases, the proteases that mediate the apoptotic response in cells. Some of these peptides have been shown to inhibit the growth of tumors in mouse models. Hopefully, pro-apoptotic anti-tumor peptides will soon be tested for their efficacy in patients with cancers.
Pubmed
Web of science
Create date
05/09/2011 8:29
Last modification date
20/08/2019 14:21
Usage data